Ramanathan, Muthalagu http://orcid.org/0000-0001-8221-3605
Kim, Soyoung http://orcid.org/0000-0003-1404-0575
He, Naya
Chen, Min
Hematti, Peiman
Abid, Muhammad Bilal
Rotz, Seth J. http://orcid.org/0000-0003-2896-1113
Williams, Kirsten M.
Lazarus, Hillard M.
Wirk, Baldeep http://orcid.org/0000-0002-2804-2531
Yin, Dwight E. http://orcid.org/0000-0002-8599-1004
Kanakry, Christopher G.
Perales, Miguel-Angel http://orcid.org/0000-0002-5910-4571
Chemaly, Roy F. http://orcid.org/0000-0002-0277-3088
Dandoy, Christopher E. http://orcid.org/0000-0002-4001-9203
Riches, Marcie
Ustun, Celalettin http://orcid.org/0000-0001-6896-6213
Article History
Received: 30 September 2022
Revised: 28 November 2022
Accepted: 2 December 2022
First Online: 21 December 2022
Competing interests
: Dr KMW reports having a R01 with NHLBI on biomarkers of engraftment; a TRP grant with Leukemia Lymphoma Society to develop a novel immunotherapy for AML; and having received payments from Rising Tide, NIH, and LLS for grant reviews. Dr MAP reports honoraria from Abbvie, Astellas, Bristol-Myers Squibb, Celgene, Equilium, Incyte, Karyopharm, Kite/Gilead, Merck, Miltenyi Biotec, MorphoSys, Novartis, Nektar Therapeutics, Omeros, OrcaBio, Takeda, and VectivBio AG, Vor Biopharma; serves on DSMBs for Cidara Therapeutics, Medigene, Sellas Life Sciences, and Servier, and the scientific advisory board of NexImmune; has ownership interests in NexImmune and Omerosl; has received research support for clinical trials from Incyte, Kite/Gilead, Miltenyi Biotec, and Novartis; received payments from Adboards/Consulting for Novartis, Merck, Omeros, Incyte. Relationships: VP, ASTCT. Dr RFC reports as a consultant and/or Advisor for Ansun BioPharma, Janssen Pharmaceuticals, Inc., Merck & Co., Inc., Oxford Immunotec USA, Inc., Pulmotect, Inc., Takeda, Genentech, Karius, ADMA Biologics, Molecular Partners, and Xenex Laboratories; having received grant/research support from Ansun BioPharma, Eurofins-Viracor, Inc., Merck & Co., Inc., Takeda; Karius, Inc., Oxford Immunotec USA, Inc., and Genentech. Dr CED has received honorarium from Omeros and Alexion Pharmaceuticals. Dr MRiches reports IQVIA Biotech, employee (as of 1/10/22); Jazz Pharmaceuticals (research funding to university- end 1/10/22); Atara Bio-Pharma (research funding to university- end 1/10/22).